Canaccord Genuity upgraded shares of Insulet Corporation (NASDAQ:PODD) from a hold rating to a buy rating in a research note published on Wednesday, MarketBeat reports. They currently have $65.00 price objective on the medical instruments supplier’s stock, up from their prior price objective of $50.00.
A number of other analysts have also recently weighed in on PODD. Jefferies Group LLC reiterated a buy rating and issued a $58.00 price target (up from $48.00) on shares of Insulet Corporation in a research report on Wednesday, August 9th. Northland Securities reiterated a buy rating on shares of Insulet Corporation in a research report on Friday, August 4th. Oppenheimer Holdings, Inc. set a $55.00 price target on Insulet Corporation and gave the company a hold rating in a research report on Friday, August 4th. BidaskClub upgraded Insulet Corporation from a buy rating to a strong-buy rating in a research report on Friday, August 25th. Finally, Cowen and Company reiterated an outperform rating and issued a $63.00 price target (up from $52.00) on shares of Insulet Corporation in a research report on Friday, August 4th. Eight research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of Buy and a consensus target price of $58.87.
Shares of Insulet Corporation (NASDAQ:PODD) opened at $69.45 on Wednesday. The company has a current ratio of 7.06, a quick ratio of 6.35 and a debt-to-equity ratio of 5.27.
Insulet Corporation (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.06. Insulet Corporation had a negative return on equity of 45.64% and a negative net margin of 6.66%. The firm had revenue of $121.80 million for the quarter, compared to analysts’ expectations of $114.02 million. During the same period in the prior year, the business posted ($0.05) earnings per share. The business’s revenue was up 28.4% compared to the same quarter last year. analysts expect that Insulet Corporation will post -0.51 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This story was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.com-unik.info/2017/11/04/insulet-corporation-podd-lifted-to-buy-at-canaccord-genuity.html.
In other news, EVP Charles Alpuche purchased 2,500 shares of the business’s stock in a transaction dated Wednesday, September 6th. The shares were acquired at an average price of $58.08 per share, with a total value of $145,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.90% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the company. Rosenblum Silverman Sutton S F Inc. CA acquired a new position in shares of Insulet Corporation during the second quarter valued at $2,122,000. Geneva Advisors LLC lifted its stake in shares of Insulet Corporation by 2.3% during the second quarter. Geneva Advisors LLC now owns 22,215 shares of the medical instruments supplier’s stock valued at $1,140,000 after acquiring an additional 504 shares during the period. Vanguard Group Inc. lifted its stake in shares of Insulet Corporation by 4.2% during the first quarter. Vanguard Group Inc. now owns 4,556,847 shares of the medical instruments supplier’s stock valued at $196,355,000 after acquiring an additional 184,465 shares during the period. Granite Investment Partners LLC lifted its stake in shares of Insulet Corporation by 0.4% during the second quarter. Granite Investment Partners LLC now owns 19,502 shares of the medical instruments supplier’s stock valued at $1,001,000 after acquiring an additional 76 shares during the period. Finally, FMR LLC lifted its stake in shares of Insulet Corporation by 0.5% during the second quarter. FMR LLC now owns 8,687,487 shares of the medical instruments supplier’s stock valued at $445,755,000 after acquiring an additional 39,836 shares during the period.
Insulet Corporation Company Profile
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
What are top analysts saying about Insulet Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Insulet Corporation and related companies.